The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - Ambrx; ATLAB Pharma; Phosplatin Therapeutics
 
Michael Philip Sun
No Relationships to Disclose
 
Jones T. Nauseef
Consulting or Advisory Role - AIQ Solutions; AIQ Solutions
Travel, Accommodations, Expenses - Digital Science Press
 
Charlene Thomas
Travel, Accommodations, Expenses - Inovio Pharmaceuticals; Nektar; Pfizer
 
Sandra Huicochea Castellanos
No Relationships to Disclose
 
Joseph Earl Thomas
No Relationships to Disclose
 
Zachary Davidson
No Relationships to Disclose
 
Judith Stangl-Kremser
No Relationships to Disclose
 
Mahelia Bissassar
No Relationships to Disclose
 
Jessica Palmer
No Relationships to Disclose
 
Angela Tan
No Relationships to Disclose
 
Amie Patel
No Relationships to Disclose
 
Ana M. Molina
Consulting or Advisory Role - EISAI; EISAi; EISAI; Exelixis; Janssen
 
Cora N. Sternberg
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Immunomedics; IMPAC Medical Systems; Incyte; Janssen Oncology; Janssen Oncology; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca; Janssen Scientific Affairs
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Exelixis (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Joseph Osborne
No Relationships to Disclose
 
Neil Harrison Bander
Leadership - Convergent Therapeutics; XenImmune Therapeutics
Stock and Other Ownership Interests - Convergent Therapeutics; Telix Pharmaceuticals; XenImmune Therapeutics
Consulting or Advisory Role - Convergent Therapeutics; XenImmune Therapeutics
Patents, Royalties, Other Intellectual Property - Patents to anti-PSMA antibodies assigned to Cornell Univ; Royalty--Cook Urological